Agreed, 10X was just a place holder for "some geometrically larger figure." If is is a buyout (which I hope it is not) then I would guesstimate the figure at $5.6 Bil based on the Allergan/Heptares deal just to license the Sigma-1 platform. Structured part upfront cash, part milestone payments and royalties. This would in effect be a wide ranging partnership and AVXL would get Biogen marketing and development muscle. A Biogen/Anavex partnership could very well be dominate CNS drug market for 30 or more years. Look at the history of Gilead that was 1600X from 1999 to present but it took some years. One of my points was that share price appreciation will be slower with partnership but greater in the long run.
But it would be very helpful to have a partner for the large indications like ALZ for marketing and development, as Dr. Missling has stated it would be and that it was his plan to partner for ALZ. I trust him.
Go AVXL!
News 
Market Data 
Discover 
AI
